Vasopressin, depression, pain & preeclampsia

Julie A. Vignato, PhD, RN, RNC-LRN, CNE,1 Sabrina Scroggins, PhD,2 Wendy Hamilton, BS,2 Debra Brandt, RN, PhD,2 Kellie Thomas, RN, BSN,2 Donna Santillan, PhD,2 Mark Santillan, MD, PhD, FACOG, FAHA,2,3

Keywords: Vasopressin, depression, pain, preeclampsia

Aims: Preeclampsia (PreE) is a prevalent hypertensive disorder of pregnancy leading to a death every minute worldwide. Predictive and preventative challenges in PreE stems from its unclear early-pregnancy etiology. Arginine vasopressin (AVP) secretion, as measured by copeptin, activates the stress response system and is a novel, early pregnancy predictor of PreE. In addition, elevated AVP is associated with stress, depression and pain. Our Precision Healthcare goal is to understand how AVP-associated changes in depression and pain affect the phenotype of PreE to develop preventative and therapeutic modalities against it. We hypothesize that in humans, antecedent depression and pain affects early pregnancy AVP secretion/copeptin which will be differentially predictive of PreE. To address this hypothesis we aim to 1) determine the association of maternal plasma copeptin and measures of depression and pain throughout human gestation and 2) determine how depression and pain through gestation affects an early pregnancy copeptin based prediction model of preeclampsia.

Methods: This nested case control study will use banked, coded, clinically-annotated maternal plasma from the Iowa Maternal Fetal Tissue Bank

1University of Iowa College of Nursing, Iowa City, Iowa
2Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA
3Maternal Fetal Tissue Bank, Division of Maternal Fetal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa


Corresponding author: Julie Vignato, PhD, RN, RNC-LRN, CNE, College of Nursing, University of Iowa, Iowa City, Iowa. Email: julie-vignato@uiowa.edu

Copyright: © 2018 Vignato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
(MFTB, IRB# 200910784) from pregnant and postpartum women. Copeptin will be measured using a commercial enzyme-linked immunosorbent assay. All clinical data including depression measures (Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale) and pain measures (Numeric Rating Scale) will be extracted from Iowa Clinical Data Warehouse associated with the MFTB. Regression modeling and receiver operating characteristic curve analyses will be performed to evaluate the association of copeptin, depression, pain and PreE.

Results

Research in progress.

Conclusions

Research in progress

Presented at “Complicated Maternal Fetal Medicine Cases,” the University of Iowa Carver College of Medicine Ob/Gyn Postgraduate Conference, 2 November 2018, Hilton Garden Inn, Iowa City, Iowa.